VERQUVO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Verquvo, and when can generic versions of Verquvo launch?
Verquvo is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are six patents protecting this drug.
This drug has two hundred and four patent family members in forty-nine countries.
The generic ingredient in VERQUVO is vericiguat. One supplier is listed for this compound. Additional details are available on the vericiguat profile page.
DrugPatentWatch® Generic Entry Outlook for Verquvo
Verquvo will be eligible for patent challenges on January 19, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 26, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VERQUVO
| International Patents: | 204 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 52 |
| Clinical Trials: | 2 |
| Patent Applications: | 153 |
| Drug Prices: | Drug price information for VERQUVO |
| What excipients (inactive ingredients) are in VERQUVO? | VERQUVO excipients list |
| DailyMed Link: | VERQUVO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VERQUVO
Generic Entry Date for VERQUVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VERQUVO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins University | Phase 2 |
| Merck Sharp & Dohme LLC | Phase 2 |
| Merck Sharp & Dohme LLC | Phase 4 |
Pharmacology for VERQUVO
| Drug Class | Soluble Guanylate Cyclase Stimulator |
| Mechanism of Action | Guanylate Cyclase Stimulators |
Anatomical Therapeutic Chemical (ATC) Classes for VERQUVO
US Patents and Regulatory Information for VERQUVO
VERQUVO is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VERQUVO is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VERQUVO
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Substituted 5-fluoro-1H-pyrazolopyridines and their use
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
Substituted 5-flouro-1H-pyrazolopyridines and their use
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
FDA Regulatory Exclusivity protecting VERQUVO
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-003 | Jan 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-002 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-003 | Jan 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-002 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VERQUVO
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | Verquvo | vericiguat | EMEA/H/C/005319 Treatment of symptomatic chronic heart failure |
Authorised | no | no | no | 2021-07-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VERQUVO
When does loss-of-exclusivity occur for VERQUVO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 98
Estimated Expiration: ⤷ Try a Trial
Argentina
Patent: 8983
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 12342547
Estimated Expiration: ⤷ Try a Trial
Patent: 17254916
Estimated Expiration: ⤷ Try a Trial
Patent: 19202123
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2014012414
Estimated Expiration: ⤷ Try a Trial
Patent: 2020001312
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 56706
Estimated Expiration: ⤷ Try a Trial
Patent: 40720
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 14001339
Estimated Expiration: ⤷ Try a Trial
Patent: 16000344
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4159898
Estimated Expiration: ⤷ Try a Trial
Patent: 5503867
Estimated Expiration: ⤷ Try a Trial
Patent: 6905314
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 60555
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 140237
Estimated Expiration: ⤷ Try a Trial
Patent: 190057
Estimated Expiration: ⤷ Try a Trial
Patent: 210072
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0161501
Estimated Expiration: ⤷ Try a Trial
Patent: 0181818
Estimated Expiration: ⤷ Try a Trial
Patent: 0210507
Estimated Expiration: ⤷ Try a Trial
Cuba
Patent: 257
Estimated Expiration: ⤷ Try a Trial
Patent: 354
Estimated Expiration: ⤷ Try a Trial
Patent: 140055
Estimated Expiration: ⤷ Try a Trial
Patent: 150123
Estimated Expiration: ⤷ Try a Trial
Patent: 150124
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Estimated Expiration: ⤷ Try a Trial
Dominican Republic
Patent: 014000112
Estimated Expiration: ⤷ Try a Trial
Patent: 017000013
Estimated Expiration: ⤷ Try a Trial
Patent: 021000179
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 14001627
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 0018
Estimated Expiration: ⤷ Try a Trial
Patent: 1602
Estimated Expiration: ⤷ Try a Trial
Patent: 3455
Estimated Expiration: ⤷ Try a Trial
Patent: 1491028
Estimated Expiration: ⤷ Try a Trial
Patent: 1690520
Estimated Expiration: ⤷ Try a Trial
Patent: 1690521
Estimated Expiration: ⤷ Try a Trial
Patent: 1892050
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Patent: 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUÉES SOUS FORME CRISTALLINE (SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES IN CRYSTALLINE FORM)
Estimated Expiration: ⤷ Try a Trial
Guatemala
Patent: 1400101
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 03951
Estimated Expiration: ⤷ Try a Trial
Patent: 23613
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 31029
Estimated Expiration: ⤷ Try a Trial
Patent: 41592
Estimated Expiration: ⤷ Try a Trial
Patent: 53745
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 2585
Estimated Expiration: ⤷ Try a Trial
Patent: 6265
Estimated Expiration: ⤷ Try a Trial
Patent: 3389
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 89315
Estimated Expiration: ⤷ Try a Trial
Patent: 40391
Estimated Expiration: ⤷ Try a Trial
Patent: 92436
Estimated Expiration: ⤷ Try a Trial
Patent: 15502932
Estimated Expiration: ⤷ Try a Trial
Patent: 17031180
Estimated Expiration: ⤷ Try a Trial
Patent: 18058860
Estimated Expiration: ⤷ Try a Trial
Patent: 18199698
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 8412
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 7481
Estimated Expiration: ⤷ Try a Trial
Patent: 14006018
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 718
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 4593
Estimated Expiration: ⤷ Try a Trial
Patent: 1592
Estimated Expiration: ⤷ Try a Trial
Patent: 4215
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 142359
Estimated Expiration: ⤷ Try a Trial
Patent: 190180
Estimated Expiration: ⤷ Try a Trial
Patent: 190181
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 014501160
Estimated Expiration: ⤷ Try a Trial
Patent: 015501494
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 387
Estimated Expiration: ⤷ Try a Trial
Patent: 945
Estimated Expiration: ⤷ Try a Trial
Patent: 609
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201604192X
Estimated Expiration: ⤷ Try a Trial
Patent: 201604196V
Estimated Expiration: ⤷ Try a Trial
Patent: 201402111Q
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 82914
Estimated Expiration: ⤷ Try a Trial
Patent: 96617
Estimated Expiration: ⤷ Try a Trial
Patent: 21470
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1403613
Estimated Expiration: ⤷ Try a Trial
Patent: 1505970
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1943788
Estimated Expiration: ⤷ Try a Trial
Patent: 1993022
Estimated Expiration: ⤷ Try a Trial
Patent: 2026059
Estimated Expiration: ⤷ Try a Trial
Patent: 140105483
Estimated Expiration: ⤷ Try a Trial
Patent: 170130612
Estimated Expiration: ⤷ Try a Trial
Patent: 190018021
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 03028
Estimated Expiration: ⤷ Try a Trial
Patent: 94158
Estimated Expiration: ⤷ Try a Trial
Patent: 64009
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 97280
Estimated Expiration: ⤷ Try a Trial
Patent: 31123
Estimated Expiration: ⤷ Try a Trial
Patent: 59016
Estimated Expiration: ⤷ Try a Trial
Patent: 65198
Estimated Expiration: ⤷ Try a Trial
Patent: 1329076
Estimated Expiration: ⤷ Try a Trial
Patent: 1708219
Estimated Expiration: ⤷ Try a Trial
Patent: 1831447
Estimated Expiration: ⤷ Try a Trial
Patent: 1838993
Estimated Expiration: ⤷ Try a Trial
Patent: 1932465
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 14000227
Estimated Expiration: ⤷ Try a Trial
Turkey
Patent: 1816203
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 6623
Estimated Expiration: ⤷ Try a Trial
Patent: 9269
Estimated Expiration: ⤷ Try a Trial
Patent: 0278
Estimated Expiration: ⤷ Try a Trial
Uruguay
Patent: 467
Estimated Expiration: ⤷ Try a Trial
Patent: 646
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VERQUVO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Montenegro | 02393 | SUPSTITUISANI 5-FLUOR-1H-PIRAZOLOPIRIDINI I NJIHOVA PRIMJENA (SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF) | ⤷ Try a Trial |
| Japan | 6392436 | ⤷ Try a Trial | |
| Eurasian Patent Organization | 201291336 | ЗАМЕЩЕННЫЕ 5-ФТОР-1Н-ПИРАЗОЛОПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ | ⤷ Try a Trial |
| South Korea | 101881174 | ⤷ Try a Trial | |
| Philippines | 12014501160 | METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H - PYRAZOLOPYRIDINES | ⤷ Try a Trial |
| China | 102939289 | Substituted 5-fluoro-1h-pyrazolopyridines and use thereof | ⤷ Try a Trial |
| Japan | 2017031180 | 置換された５−フルオロ−１Ｈ−ピラゾロピリジン類を製造するための方法 (PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VERQUVO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2576547 | PA2021518,C2576547 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716 |
| 2576547 | 21C1038 | France | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; REGISTRATION NO/DATE: EU/1/21/1561 20210720 |
| 2576547 | 122021000048 | Germany | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 20210716 |
| 2576547 | C02576547/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68001 22.09.2021 |
| 2576547 | 2021C/553 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720 |
| 2576547 | CA 2021 00032 | Denmark | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720 |
| 2576547 | 301146 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: EU/1/21/1561 20210720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
